<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04852003</url>
  </required_header>
  <id_info>
    <org_study_id>SHR0410-301</org_study_id>
    <nct_id>NCT04852003</nct_id>
  </id_info>
  <brief_title>A Trial of SHR0410 Injection for the Treatment of Pain After Endoscopic Surgery of the Lower Abdominal</brief_title>
  <official_title>A Phase Ⅲ, Randomized, Double-blind, Placebo- and Active-controlled Study of SHR0410 Injection for the Treatment of Pain After Endoscopic Surgery of the Lower Abdominal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the efficacy and safety of SHR0410 injection for the&#xD;
      treatment of pain after endoscopic surgery of the lower abdominal.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>SHR0410 injection compared with placebo and morphine</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The area under the curve of pain intensity over 24 hours</measure>
    <time_frame>24-hours</time_frame>
    <description>Pain intensity will be evaluated using an 11-point (0-10) numeric rating scale (NRS), with higher numbers indicating a higher pain intensity, administered over 24 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total consumption of remedial analgesics from 0h to 24h</measure>
    <time_frame>24-hours</time_frame>
    <description>Total consumption of IV morphine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant ' satisfaction score for analgesia treatment</measure>
    <time_frame>24-hours</time_frame>
    <description>Participants recalled the postoperative analgesia effect and rated their satisfaction on a scale of 0 to 10, with 0 representing dissatisfied and 10 representing very satisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator satisfaction score for analgesia treatment</measure>
    <time_frame>24-hours</time_frame>
    <description>Postoperative analgesia was evaluated by investigators. The scale ranges from 0 to 10, with 0 being dissatisfied and 10 being very satisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>Day 4（or early termination on Day 3）</time_frame>
    <description>Assessed by monitoring of adverse events. Participants with adverse events found to be related to the study drug will be compared to those receiving placebo or active comparator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by vital signs</measure>
    <time_frame>Day 4（or early termination on Day 3）</time_frame>
    <description>Changes in vital signs such as body temperature, blood pressure, heart rate will be assessed at specified times.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by laboratory evaluations</measure>
    <time_frame>Day 4（or early termination on Day 3）</time_frame>
    <description>Assessed by laboratory evaluations at specified times. Participants with clinically significant lab values will be compared to those receiving placebo or active comparator.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>SHR0410 Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for SHR0410 Injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR0410 Injection</intervention_name>
    <description>SHR0410 Injection</description>
    <arm_group_label>SHR0410 Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for SHR0410 Injection</description>
    <arm_group_label>Placebo for SHR0410 Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>Morphine</description>
    <arm_group_label>Morphine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able and willing to provide a written informed consent&#xD;
&#xD;
          2. Subjects requiring elective general anesthesia endoscopic surgery of the lower&#xD;
             abdominal&#xD;
&#xD;
          3. Male or female&#xD;
&#xD;
          4. Meet the body mass index standard&#xD;
&#xD;
          5. Conform to the ASA Physical Status Classification&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Subjects with a history of difficult airway&#xD;
&#xD;
          2. Subjects with a history of mental illness&#xD;
&#xD;
          3. Subjects with a history of cognitive impairment epilepsy&#xD;
&#xD;
          4. Subjects with a history of myocardial infarction or unstable angina pectoris&#xD;
&#xD;
          5. Subjects with atrioventricular block or cardiac insufficiency&#xD;
&#xD;
          6. Subjects with a history of ischemic stroke or transient ischemic attack&#xD;
&#xD;
          7. Subjects with poor blood pressure control after medication&#xD;
&#xD;
          8. Subject with a history of substance abuse and drug abuse&#xD;
&#xD;
          9. Abnormal values in liver function&#xD;
&#xD;
         10. Subjects with an oxygen saturation below 90% on room air&#xD;
&#xD;
         11. Allergic to drugs that may be used during the study&#xD;
&#xD;
         12. Pregnant or nursing women&#xD;
&#xD;
         13. No birth control during the specified period of time&#xD;
&#xD;
         14. Participated in clinical trials of other drugs (received experimental drugs)&#xD;
&#xD;
         15. The investigators determined that other conditions were inappropriate for&#xD;
             participation in this clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yang Zhang, M.M</last_name>
    <phone>+0518-82342973</phone>
    <email>yang.zhang@hrglobe.cn</email>
  </overall_contact>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 15, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

